

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



YUNKANG GROUP LIMITED

云康集团有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2325)

CHANGE OF NON-EXECUTIVE DIRECTOR

This announcement is made by Yunkang Group Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) under Rule 13.51(2) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”, each a “**Director**”) of the Company hereby announces that Mr. Zhou Weiqun (周偉群) (“**Mr. Zhou**”) has tendered his resignation as a non-executive Director of the Company with effect from July 11, 2022 in order to devote more time to his personal endeavours. Mr. Zhou has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company and the Stock Exchange. The Board would like to take this opportunity to express its gratitude to Mr. Zhou for his contribution to the Group during the tenure of his office.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Dr. Wang Ruihua (王瑞華) (“**Dr. Wang**”) has been appointed as a non-executive Director of the Company with effect from July 11, 2022. The biographical details of Dr. Wang are as follows:

Dr. Wang, aged 60, served as a director of MBA Education Center of Central University of Finance and Economics (中央財經大學MBA教育中心) from July 2006 to September 2019, and served as the president of Business School of Central University of Finance and Economics (中央財經大學商學院) from December 2012 to September 2019. Since September 2020, Dr. Wang has been serving as the executive president and a professor of the Central University of Finance and Economics, Greater Bay Area Research Institute (中央財經大學粵港澳大灣區(黃埔)研究院).

Dr. Wang has over 10 years of experience as director of listed companies. From April 2008 to April 2014 and from May 2015 to March 2021, Dr. Wang served as an independent director of Beijing Zhong Ke San Huan Hi-Tech Co., Ltd. (北京中科三環高技術股份有限公司), the shares of which are listed on the Shenzhen Stock Exchange (stock code: 000970). From March 2011 to June 2017 and since September 2019, Dr. Wang served and has been serving as an independent director of Anhui Gujing Distillery Company Limited (安徽古井貢酒股份有限公司), the shares of which are listed on the Shenzhen Stock Exchange (stock code: 000596). From February 2015 to May 2020, Dr. Wang served as an independent director of Harbin Gloria Pharmaceuticals Co., Ltd. (哈爾濱譽衡藥業股份有限公司), the shares of which are listed on the Shenzhen Stock Exchange (stock code: 002437). Since December 2019, Dr. Wang has been serving as an independent director of Bank of Beijing Co., Ltd. (北京銀行股份有限公司), the shares of which are listed on the Shanghai Stock Exchange (stock code: 601169). Since March 2020, Dr. Wang has been serving as an independent director of BCEG Environmental Remediation Co., Ltd. (北京建工環境修復股份有限公司), the shares of which are listed on the Shenzhen Stock Exchange (stock code: 300958).

Dr. Wang obtained his PRC certified public accountant certificate from the Chinese Institute of Certified Public Accountants (中國註冊會計師協會) in September 1996.

In July 1983 and July 1987, Dr. Wang obtained his bachelor's and master's degrees in economics from Central Institute of Finance and Banking (中央財政金融學院) (currently known as Central University of Finance and Economics (中央財經大學)), respectively. In July 2003, Dr. Wang obtained his doctoral degree of management from Central University of Finance and Economics.

Dr. Wang has entered into an appointment letter with the Company for a term of three years commencing from the date of appointment as Director, and shall be subject to re-election as and when required under the articles of association of the Company. Dr. Wang will receive salary and director's fee from the Company in the amount of HK\$250,000 per annum which has been determined by reference to his background, qualifications, experience, level of responsibilities to be undertaken with the Company and prevailing market conditions. Dr. Wang will hold office until the next following annual general meeting of the Company and shall then be eligible for re-election in accordance with the articles of the Company.

As at the date of this announcement, Dr. Wang does not have any interest in or is deemed to be interested in any shares or underlying shares of the Company or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance.

As of the date of this announcement and save as disclosed above, Dr. Wang (i) has not held any other directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years preceding the date of this announcement or any other major appointments and professional qualifications; (ii) does not hold any other positions in the Company and other members of the Group; and (iii) does not have any other relationship with any other Directors and senior management.

Save as disclosed in this announcement, Dr. Wang has confirmed that there is no other information which requires to be disclosed pursuant to Rule 13.51(2) of the Listing Rules nor is there any other matter regarding his appointment that need to be brought to the attention of the shareholders of Company and/or the Stock Exchange.

The Board would like to take this opportunity to welcome Dr. Wang in joining the Board.

By order of the Board
Yunkang Group Limited
Zhang Yong
Chairman

Guangzhou, the PRC
July 11, 2022

As at the date of this announcement, the executive Director, Chairman and Chief Executive Officer of the Company is Mr. Zhang Yong; the non-executive Directors of the Company are Mr. Zhou Xinyu, Dr. Guo Yunzhao and Dr. Wang Ruihua; and the independent non-executive Directors of the Company are Mr. Yu Shiyong, Mr. Yang Hongwei and Mr. Xie Shaohua.